Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 16:35:100439.
doi: 10.1016/j.jctube.2024.100439. eCollection 2024 May.

Characteristics and outcomes of the duration of treatment with adjunctive corticosteroids in intraocular tuberculosis

Affiliations

Characteristics and outcomes of the duration of treatment with adjunctive corticosteroids in intraocular tuberculosis

Yaninsiri Ngathaweesuk et al. J Clin Tuberc Other Mycobact Dis. .

Abstract

Introduction: Intraocular tuberculosis (IOTB) is a common site of extrapulmonary tuberculosis and a main cause of infectious uveitis. It can result in severe visual morbidity if not recognized and treated properly. The clinical manifestations of IOTB are varied, and the duration of treatment is unclear. This study describes the clinical characteristics and outcomes of patients with IOTB and compares the duration of antituberculosis therapy (ATT) and steroid use.

Method: An 8-year retrospective study of IOTB patients in an endemic area of a tertiary hospital in Thailand. All patients had a complete treatment of ATT at least for 6 months.

Results: Forty-three patients with 57 eyes and a mean age of 43.72 years were included. Panuveitis (38.6 %), retinal phlebitis (31.6 %), and posterior uveitis (15.8 %) were common clinical characteristics. A significant difference between initial and final best corrected visual acuity (BCVA) after ATT in 6 months for therapy and at least 9 months for therapy was observed (p = 0.004, 0.003, respectively). Ninety point nine percent of patients who received ATT for 9 months achieved a successful treatment outcome, while 66.7 % of patients who received ATT for 6 months did (p = 0.056). Patients who received systemic and/or regional corticosteroids therapy during treatment had a higher rate of treatment failure (p < 0.001).

Conclusion: IOTB had a variety of clinical manifestations, including nongranulomatous inflammation. Patients who completed treatment with ATT for at least 6 months improved their final BCVA. There was no difference in treatment outcomes regarding the duration of treatment. Combined treatment with systemic and/or regional corticosteroids was significantly associated with failed treatment outcomes.

Keywords: Antituberculosis therapy; Intraocular tuberculosis; Retinal vasculitis; Steroid; Uveitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
A) The right fundus shows multiple occlusive retinal phlebitis at midperiphery. B) The left fundus shows tuberculoma size 2 disc diameter at superior of posterior pole.

References

    1. World Health Organization, ‘Global Tuberculosis report 2022’, 2022. [Online]. Available: http://apps.who.int/bookorders.
    1. World Health Organization, ‘Global Tuberculosis report 2021’, 2021. [Online]. Available: http://apps.who.int/bookorders.
    1. A. Abdisamadov and O. Tursunov, ‘Ocular tuberculosis epidemiology, clinic features and diagnosis: A brief review’, Tuberculosis, vol. 124. Churchill Livingstone, Sep. 01, 2020. doi: 10.1016/j.tube.2020.101963. - PubMed
    1. S. Sukavatcharin, O. Kijdaoroong, K. Lekhanont, and S. Arj-Ong Vallipakorn, ‘Pattern of Uveitis in a Tertiary Ophthalmology Center in Thailand’, Ocul Immunol Inflamm, vol. 25, pp. S94–S99, Aug. 2017, doi: 10.1080/09273948.2016.1215475. - PubMed
    1. I. Testi et al., ‘Ocular tuberculosis: Where are we today?’, Indian Journal of Ophthalmology, vol. 68, no. 9. Wolters Kluwer Medknow Publications, pp. 1808–1817, Sep. 01, 2020. doi: 10.4103/ijo.IJO_1451_20. - PMC - PubMed

LinkOut - more resources